Insulin Sensitizer Protects Against Heart Attacks

Susan Farley
Published Online: Tuesday, November 1, 2005

A large clinical study found that the diabetes drug pioglitazone reduced the combined risk of heart attacks, strokes, and death, in addition to lowering blood sugar levels. The study compared the drug against conventional therapy in 5200 high-risk patients with type 2 diabetes and found that the drug made the body's cells more sensitive to insulin. Pioglitazone belongs to a class of drugs known as insulin sensitizers, which include Actos, manufactured by Takeda Pharmaceutical Co Ltd, and GlaxoSmithKline's Avandia. The results of this study indicate that 10 to 11 heart attacks, strokes, or deaths could be prevented for every 500 high-risk patients who are treated with pioglitazone over a 3-year period.

Ms. Farley is a freelance medical writer based in Wakefield, RI.

Latest Articles
OTC medications can have serious side effects in children if they are not carefully administered.
Patients with asthma can now access Spiriva Respimat with a prescription at pharmacies across the country.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
Latest Issues